Gliobastoma + New View on Clinical Trials... Dr. Fahar Merchant, President & CEO Medicenna Therapeutics

BioTech Nation ... with Dr. Moira Gunn

Glioblastoma is the most aggressive form of brain cancer, and progress in treating Glioblastoma has been elusive. Now, Toronto-based Medicenna has completed a successful Phase 2 with its innovative drug, and is now deep into planning the Phase 3 Trial. Also of interest, the FDA agreed to an unprecedented approach in Phase 2, which not only yields better science, but reduces the cost of the clinical trials themselves. To be sure, this approach will be carried forward into Phase 3. Dr. Fahar Merchant is the President & CEO of Medicenna Therapeutics.